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Abstract
Insulin-producing stem cell-derived islets (SC-islets) provide a virtually unlimited cell source for diabetes cell replacement therapy. While
SC-islets are less functional when first differentiated in vitro compared to isolated cadaveric islets, transplantation into mice has been
shown to increase their maturation. To understand the effects of transplantation on maturation and function of SC-islets, we examined the
effects of cell dose, transplantation strategy, and diabetic state in immunocompromised mice. Transplantation of 2 and 5, but not 0.75 million SC-islet cells underneath the kidney capsule successfully reversed diabetes in mice with pre-existing diabetes. SQ and intramuscular
injections failed to reverse diabetes at all doses and had undetectable expression of maturation markers, such as MAFA and FAM159B.
Furthermore, SC-islets had similar function and maturation marker expression regardless of diabetic state. Our results illustrate that transplantation parameters are linked to SC-islet function and maturation, providing ideal mouse models for preclinical diabetes SC therapy
research.
Key words: stem cells; tissue-based therapy; diabetes mellitus; cell transplantation; insulin-secreting cells.

Graphical Abstract

Introduction
Diabetes is a metabolic disorder resulting from the death
and dysfunction of insulin-producing β cells found within
pancreatic islets. Cell replacement therapy is a potential
treatment for patients with diabetes. Human pluripotent
stem cell-derived islets (SC-islets) that transcriptionally and
functionally resemble primary human islets are a potential
renewable source of replacement cells.1-4 Recent advances
have enabled differentiation of SC-islets with high endocrine purity, including hormone-secreting β, α, and δ cells,
that undergo glucose-stimulated insulin secretion (GSIS)
and successfully treat or prevent diabetes in mice.5-9 This
technology has facilitated the study of patient-derived
SC-islets with diabetes, and explored employment of geneediting strategies to reverse diabetes-causing gene variants.
In addition, SC-islets have expanded the understanding of
islet cell maturation molecular controls and differentiation
in vitro.10-16

Despite these advances, SC-islets, particularly the β cells,
are still immature when compared to isolated cadaveric islets both in terms of function and marker expression in vitro.
Maturation has been described to occur after transplantation in mice in terms of function and marker expression.17-19
Both non-diabetic mice and mice with pre-existing diabetes
are used in studies.5,6,10-12,14,17,18,20-24 Transplanting cells into
nondiabetic mice prevents subsequent induction of diabetes,
such as by streptozotocin (STZ) injection, but does not establish their ability to reverse it. The reported cellular doses
transplanted vary widely in reports.12,17,18,20,23,25-27 Location
also varies, with common transplantation strategies including
the SQ,22 intramuscular (IM),14 epididymal or mammary fat
pad,27 and kidney capsule (KC) locations.5,11,17,28 The effects of
dose, location, and diabetic state on function and maturation
of SC-islets are unknown but relevant for clinical translation.
Furthermore, a careful, controlled comparison of these important parameters has not been performed for SC-islets.
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Materials and Methods
Cell Culture and Differentiation
Undifferentiated HUES8 human embryonic stem cells
(hESCs) were graciously provided by Dr. Douglas Melton
(Harvard University), were cultured in mTeSR1 (STEMCELL
Technologies; 05850) on tissue culture plastic in a humidified 5% CO2 37°C tissue culture incubator. Every 3-4 days,
SCs were passaged by single-cell dispersion using TrypLE
(Life Technologies; 12-604-039), counted with Vi-Cell
XR (Beckman Coulter), and seeded 0.52 × 106 cells/cm2 in
mTeSR1 + 10 mM Y27632 (Abcam; ab120129) on Matrigelcoated (Corning; 356230) plates. To initiate differentiation,
undifferentiated SCs were seeded at 5 × 106 cells per well in
a Matrigel-coated 6-well plate. Subsequent feeding schedules,
media formulations, and differentiation factors are provided
in Supplementary Tables S1 and S2. On day 7 of stage 6, cells
are single-cell dispersed using TrypLE and seeded at 5 × 106
cells per well with 4 mL of stage 6 into a 6-well plate. The
cells are cultured on an orbi-shaker (Benchmark) rotating at
100 RPM in a humidified 5% CO2 37°C tissue culture incubator. Brightfield images are taken throughout differentiation
with a Leica DMi1.

Immunostaining
SC-islets or transplanted cell extractions were fixed with 4%
paraformaldehyde (Electron Microscopy Science; 15714)
overnight at 4°C. SC-islet clusters were placed in Histogel
(Thermo Fisher Scientific; Hg-4000-012) and transplant extractions were cut in half and processed by the Division of
Comparative Medicine (DCM) Research Animal Diagnostic
Laboratory Core at Washington University and Histowiz.
Paraffin was removed with Histoclear (Electron Microscopy
Sciences; 64111-04) and ethanol (Decon; 2716), samples
were rehydrated, and antigens were retrieved in a pressure
cooker (Proteogenix; 2100 Retriever) with 0.05M EDTA
(Ambion; AM9261). Samples were blocked and primary antibodies were diluted in immunostaining buffer (5% Donkey
Serum [Jackson Immunoresearch; 017-000-121]) and 0.1%
Triton-X (Acros Organics; 327371000) in phosphate-buffered
saline (PBS) (Corning; 21-040-CV)) and applied to samples
overnight at 4°C in a humidified box. Next, secondary antibodies diluted in immunostaining buffer were added for 2 h
at room temperature (RT), and then samples were mounted
with DAPI Fluoromount-G (SouthernBiotech; 0100-20). Cells
were imaged with a Leica DMI4000 fluorescence or Nikon
A1Rsi confocal microscope. Images were processed with
ImageJ. Flow cytometry was performed on single-cell dispersed SC-islets with TrypLE, fixed at RT for 30 minutes, and
stained as described above. Cells were analyzed with BD LSR

Fortessa X-20 (BD Biosciences). FlowJo software generated
population percentages and dot plots. Antibody details and
dilutions are available in Supplementary Table S3.

Glucose-Stimulated Insulin Secretion
SC-islets were washed with Krebs-Ringer Bicarbonate (KRB)
buffer (128 mM NaCl, 5 mM KCl, 2.7 mM CaCl2 1.2 mM
MgSO4, 1 mM Na2HPO4, 1.2 mM KH2PO4, 5 mM NaHCO3,
10 mM HEPES [Gibco; 15630-080], and 0.1% bovine serum
albumin [BSA]) and transferred to transwells in 2 mM glucose KRB solution for 1 h to equilibrate. The solution was
replaced with 2 mM glucose KRB for an additional 1 h and
supernatant was collected. Last, solution was replaced with
20 mM glucose KRB for the final 1 h and supernatant was
collected. Transwells were transferred to TrypLE for singlecell dispersion, incubated for 30 minutes, and counted with
Vi-Cell XR to normalize insulin secretion. Insulin in supernatant was quantified with human insulin ELISA (ALPCO;
80-INSHU-E10.1). For all incubations, cells were placed in a
humidified incubator at 37°C with 5% CO2.

Transplantation Studies
All transplantation studies adhered to Institutional Animal
Care and Use Committee regulations. All studies and surgeries were performed by unblinded individuals and mice
were randomly assigned to experimental groups. Seven-weekold male NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were
ordered from Jackson Laboratories (005557). Mice were rendered diabetic (blood glucose >500 mg/dL) with 5 consecutive
days of 45 mg/kg STZ (R&D systems; 1621400) injections.
Diabetic and nondiabetic mice were anesthetized and injected
with a designated number of SC-islet cells in clusters according to their experimental group—(dose) 5 × 106, 2 × 106,
or 0.75 × 106 into the KC of diabetic mice; (strategy) 5 × 106
into the KC, IM, SQ, or intraperitoneal of diabetic mice; (diabetic state) 5 × 106 into the KC of diabetic and nondiabetic
mice. Sham diabetic and nondiabetic mice were used as controls. Sample size was not determined using a power calculation. KC transplants were performed with a 25G butterfly
needle (TERUMO; SV∗25BLK). Cells transplanted in the IM,
SC, or IP locations were injected with ~50 µL of Matrigel
using a 27G needle (BD; 309623). For IM, cells were transplanted into the left thigh muscles. For SC, cells were transplanted on the left side of the back at the midline. SC-islet
cells were produced from the same batch of differentiation to
avoid potential confounding influence of batch-to-batch variation in the quality of the cells.
Blood glucose was measured with Contour NEXT Blood
Glucose Monitoring System (Bayer). Random insulin serum
was quantified throughout the study by tail bleed collection
into microvettes (16.443.100, Sarstedt). Whole blood was
centrifuged for 15 minutes at 2500 rpm at 4°C, serum was
collected and stored at −80°C. Random weight measurements
were taken on a scale (Adam Equipment; AE9CQ15186).
Functional assessments included glucose tolerance test
(GTT) and in vivo GSIS. For both assessments, mice were
fasted for 4 h and injected with 2 g/kg glucose in 0.9% saline (MOLTOX; 51-405022.052). For GTT, blood glucose
was measured every 30 minutes for 120 minutes. For in
vivo GSIS, blood was collected using microvettes before and
1 h after glucose stimulation, centrifuged, and serum supernatant was transferred for storage at −80°C. Serum hormones
were quantified with Mouse C-Peptide ELISA (ALPCO
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Here, we report the effects of dose, location, and diabetic
state on transplanted SC-islets in immune-compromised mice.
SC-islets were differentiated in vitro using a 6-stage differentiation protocol5 and transplanted animals were monitored
for up to 22 weeks. Transplantation with as few as 2 million
cells underneath the KC reversed pre-existing STZ-induced
diabetes while 0.75 million cells were insufficient. However,
the recipient mice with pre-existing diabetes did not affect
neither human C-Peptide levels in the serum nor maturation
marker expression of the transplanted SC-islets. Other locations failed to both reverse diabetes and express maturation
markers.
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Immunostaining Quantification
Sectioned slides were stained with islet (C-Peptide, Glucagon
[GCG], Somatostatin), maturation markers (MAF BZIP
transcription factor A [MAFA] and FAM159B), and DAPI
as described above. For FAM159B, GCG, somatostatin,
and C-Peptide, at least 3 representative images were taken
for each transplant condition from up to 4 mice, starting at
14-week post-transplant. For MAFA, at least 3 representative
images were taken for each transplant condition for 1 mouse
at 14 wk post-transplant, as the supply of antibody for this
study was limited. The number of cells per sectioned transplant
ranged from 50-400 total cells, depending on the transplant
condition and view of graft. For islet markers, the number
of monohormonal (eg, C-Peptide+GCG− or C-Peptide−
GCG+) and total number of grafted cells were counted. The
ratio of specific islet cell types to the total cell number was
calculated as a percentage. For maturation markers, the
number of C-Peptide+ (green), and C-Peptide+MAFA+ or
C-Peptide+FAM159B+ (green and red) cells were counted.
The ratio of C-Peptide+MAFA+ or C-Peptide+FAM159B+ to
C-Peptide+ was calculated as a percentage.

Statistical Analysis
Statistical analysis was performed with GraphPad Prism
8.2.1. Two-sided unpaired and paired t-tests and one-way
analysis of variance with Dunnet’s or Tukey’s multiple comparison test were performed when appropriate. Statistical
tests are detailed in figure legends with sample size, n,
indicating a total number of biological replicates. Data are
shown as mean ± SEM. P < .05 was considered statistically
significant.

Results
In Vitro Differentiation of SC-Islets Before
Transplantation
hESCs were differentiated into SC-islets with a recent differentiation protocol (Fig. 1A).5 The SC-islets resembled primary
human islet morphology, composition, and function (Fig. 1B
and E).5,6,10,29 This differentiation protocol produced almost
exclusively endocrine (CHGA+) cells (93 ± 3%) (Fig. 1D).
SC-β cells were the most prominent cell type generated in
SC-islets, defined by C-Peptide+NKX6.1+ cells, which is consistent in multiple differentiations and when sampling multiple clusters (42 ± 6%) (Fig. 1C and D). SC-islets were able
to undergo GSIS, secreting more insulin in response to glucose
(P = .0011, 2 mM, 487 ± 71, 20 mM, 1655 ± 216 µIU/106
cells) (Fig. 1E).6,10

SC-islets were transplanted to investigate the impact of multiple strategies (KC, IM, SQ), doses (5, 2, 0.75 million), and
diabetic state (STZ and no STZ control) on maturation and
function (Fig. 1F and 1G, Supplementary Fig. S1A). SC-islet
transplant conditions were all performed in 8- to 10-weekold NSG immunodeficient mice from Jackson Laboratories.
We used low-dose STZ injections over 5 days to render diabetes in the NSG mice. STZ-induced diabetic mice with sham
transplants were established as controls throughout the study.
Several mice with low amounts of circulating human insulin
and all the STZ-induced diabetic mice were sacrificed at week
14 due to health concerns. The remaining mice were studied
for 22 weeks to investigate the maturation, function, and
ability to return blood glucose levels to euglycemia.

KC Transplantation Reversed Diabetes in Mice
For this study, we transplanted 5 million SC-islet cells into
mice at various locations including KC, IM, and SQ (Fig. 1G).
Weekly fasting blood glucose measurements revealed KC
transplants (blue) as the only location to reverse diabetes at 6
weeks post-transplantation (Fig. 2A). The SQ (green) and IM
(orange) transplanted mice remained hyperglycemic with the
lowest fasted weekly blood glucose measurement observed as
355 ± 19 mg/dL at week 14 and 340 ± 32 mg/dL at week
3, respectively. Interestingly, the IM strategy showcased high
and low blood glucose spikes from weeks 1 to 12 until the
values plateaued averaging 578 ± 14 mg/dL from week 12
onward (Fig. 2A). Furthermore, the SQ location, averaging
blood glucose 458 ± 40 mg/dL over 22 weeks, had some
reduction in blood glucose, maintaining less severe hyperglycemia than the IM transplants from week 3 until the conclusion of the study (Fig. 2A). Vascularization and SC-islet
grafts were visible in all explanted strategy sites at 14- and
22-weeks post-transplantation (Fig. 1G, Supplementary Fig.
S1A and B). Furthermore, weight remained similar between
transplanted mice however, the diabetic no transplant (gray)
mice weighed less beginning at week 2 compared to all transplanted groups (P = .02) (Supplementary Fig. S2A).
We collected random mouse serum, and quantified human
C-Peptide measurements which indicated less C-Peptide secretion in IM and SQ transplants compared to the KC (Fig.
2B). We performed a GTT and in vivo GSIS to determine glucose tolerance and glucose-responsive insulin secretion, respectively. We conducted the assays after 4 h fasts with an
intraperitoneal injection of 2 mg/kg glucose. Remarkably,
all strategies contained functional SC-islets at 6 weeks posttransplantation yielding a stimulation index greater than 1.0
(KC, 3.6 ± 0.9; IM, 10.2 ± 5.6; SQ, 1.9 ± 0.7; P = .21) (Fig.
2C). However, the SQ and IM strategies had lower insulin
secretion at both low and high glucose compared to the KC
transplants (Fig. 2C). A high functioning graft requires both
high concentrations of C-Peptide and an in vivo stimulation
index, which is only identified in the KC transplant. This is
further supported by weekly blood glucose monitoring and
random C-Peptide values. The only glucose tolerant mice at
6 weeks post-transplantation contained the KC transplant,
whereas the IM and SQ strategies remained hyperglycemic
throughout the 120 minutes assay (Fig. 2D).
At least one animal per condition was sacrificed at week
14 to determine composition and maturation of the sectioned
grafts. Up to 3 additional animal grafts were collected up to
week 22 for histological analysis. For all locations, C-Peptide
expressing SC-β cells were present as well as GCG+ SC-α and
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Diagnostics; 80-CPTMS-E01), Human Ultrasensitive
C-Peptide ELISA (Mercodia; 10-1141-01), Human Proinsulin
ELISA, and Human Ultrasensitive Insulin ELISA (ALPCO
Diagnostics; 80-ENSHUU-E01.1). Random mouse serum was
collected in the AM (7:00-11:00) and GTT was performed
in the PM (12:00-16:00). Nephrectomy was performed on
mice with reversed diabetes by removing kidney with transplanted SC-islets. The blood glucose, weight, in vivo GSIS,
random C-Peptide, and GTT data for the STZ, 5M KC mouse
(royal blue) condition and diabetic controls (STZ, No Txp,
gray) were repeatedly used in Figs. 2-4 and Supplementary
Fig. S2 for multiple different transplantation methodology
comparisons.
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somatostatin+ SC-δ cells (Fig. 2E, Supplementary Fig. S2B
and C). For the IM transplants, fewer C-Peptide+ SC-β and
GCG+ SC-α cells were present and the GCG protein presence was weak compared to the mice implanted in the KC
(Supplementary Fig. S2B). We immunostained FAM159B and
MAFA, both of which are maturation markers for β cells and
associated with post-transplantation maturation for SC-β
cells,30,31 to determine maturation of the SC-islets in vivo. They
were also specific to pancreatic endocrine, distinguishing cells
from exocrine32 which were present in the grafts, as previously
reported,5 but not in stage 6 SC-islets in vitro (Supplementary
Fig. S2D). FAM159B encodes a membrane protein that

regulates exocytosis therefore the FAM159B+C-Peptide− cells
may be identified as other endocrine hormone-secreting cell
types (Fig. 2E and Supplementary Fig. S2B). Several C-Peptide
cells coexpressed FAM159B in the KC graft indicating maturation of the SC-β cells (Fig. 2E, Supplementary Fig. S2B and
C). The IM location had no FAM159B expression and surprisingly, the SQ graft had several FAM159B+ cells, however, few
were coexpressed with C-Peptide (Figs. 2E, Supplementary Fig.
S2B and C). MAFA is a well-known maturation marker for β
cells5,17,31,33 and is present in a high percentage of C-Peptide+
SC-β cells when transplanted in the KC31 (59 ± 4%, Fig. 2E
and Supplementary Fig. S2E). Alternatively, the IM and SQ

Downloaded from https://academic.oup.com/stcltm/article/11/3/322/6549674 by Washington University School of Medicine Library (M1) user on 22 December 2022

Figure 1. Characterization of stem cell-derived islets (SC-islets) in vitro. (A) Schematic of 6-stage differentiation protocol to generate SC-islets. (B)
Brightfield images of stage 6 SC-islets generated in vitro. Scale bar = 250 µm. (C) Immunostained sections and (D) representative flow cytometry
plots of stage 6 SC-islets for islet and β cell markers. Scale bar = 50 µm. (E) Static GSIS of SC-islets in vitro (n = 4, replicates transplanted in mice).
(F) Schematic of different transplantations assessed in the study. (G) Images of explanted grafts in kidney capsule (KC), subcutaneous (SQ), and
intramuscular (IM) locations. Black boxes frame graft and white arrows point to blood vessel formation. Results are mean ± SEM. CP, C-Peptide, green;
NKX6.1, red; DAPI, DAPI, 4ʹ,6-diamidino-2-Phenylindole, blue.
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grafts contained no MAFA+C-Peptide+ cells (SC, 0 ± 0%,
IM, 0 ± 0 %), implying a lack of maturation with these strategies (Fig. 2E and Supplementary Fig. S2E). Furthermore, we
immunostained grafted and in vitro SC-islets with MAFB
following transplantation (Supplementary Fig. S2F). In summary, the KC transplantation location was more advantageous compared to IM and SQ when assessing SC-islet cell
therapy due to its ability to reverse diabetes in mice and mature SC-islets in vivo.

A Dose of 5 and 2 Million SC-Islet Cells reversed
Diabetes in Mice
In previous reports, we transplanted 5 million cells into the
KC.5,6,10 To determine if fewer cells could produce similar
results, we reduced the number of transplanted cells in this
study, surveying the cell therapy potential of 5 (dark blue),
2 (medium blue), and 0.75 (light blue) million SC-islet cells
transplanted into the KC of mice with pre-existing diabetes.
Weekly blood glucose measurements revealed the reversal of
diabetes in mice with 5 and 2 million transplanted SC-islet

cells (Fig. 3A and B). Alternatively, the 0.75 million SC-islet
transplants failed to reverse diabetes throughout the 22-week
study, with mice remaining severely hyperglycemic and
displaying significant weight loss (28 ± 1 g, week 7) beginning
at week 7 until the completion of the study, relative to the 2
(30.5 ± 0.6 g, week 7, P = .045) and 5 (31.2 ± 0.8 g, week 7,
P = .016) million SC-islet transplanted mice (Fig. 3A and B,
Supplementary Fig. S3A).
Circulating human C-Peptide in the mouse serum 2 weeks
post-transplant was greater in the 2 and 5 million SC-islet
doses compared to the 0.75 million SC-islet transplanted
mice (Fig. 3C). At 6 weeks post-transplantation, 2 and 5
million SC-islet transplanted mice attained euglycemia and
in vivo GSIS displayed glucose-responsive C-Peptide secretion for the nondiabetic transplanted mice (Fig. 3D).
Furthermore, the mice transplanted with 2 and 5 million
cells had indistinguishable glucose tolerance indicated by
GTT at week 6 (Fig. 3E), whereas the 0.75 million SC-islet
transplanted mice had dysfunctional, low insulin-secreting
cells lacking glucose tolerance with a GTT profile similar to
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Figure 2. Transplantation of stem cell-derived islets (SC-islets) in diabetic mice using multiple strategies. (A) Blood glucose before and after STZ
treatment and transplantation of 5 million SC-islet cells into the kidney capsule (KC; streptozotocin [STZ], KC 5M; blue, n = 4), subcutaneous space
(STZ, SQ 5M; green, n =4), or in the muscle (STZ, IM 5M; orange, n = 4), and diabetic (STZ, No TxP; dark gray, n =4) controls (n = 4). (B) Random serum
human C-Peptide measurement in all transplant sites (n = 4) at 2 weeks post-transplantation. ∗∗∗∗P < .0001 by 2-way unpaired t-test. (C) In vivo GSIS at
6 weeks post-transplantation for all transplant strategies in diabetic mice at 0 and 60 minutes following 2 g/kg intraperitoneal glucose injection (n = 4).
∗P < .05 by 2-way paired t-test comparing 0- and 60-minutes time points. #P < .05, ##P < .01 by 2-way unpaired t-test comparing 60 minutes timepoint
from IM and SQ to KC. (D) Glucose tolerance test (GTT) blood glucose and area under the curve (AUC) quantification at 6 weeks after transplant (n = 4).
∗∗P < .01, ∗∗∗P < .001 by 2-way unpaired t-test compared between transplantation strategies. (E), Representative images of immunostained sectioned
graft explanted from each mouse transplantation location at 14 weeks post-transplantation for islet and beta-cell maturation markers. Scale bar = 100
µm. SST, somatostatin. See also Supplementary Fig. S2. Results are mean ± SEM.
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the diabetic controls (gray) (Fig. 3E). We performed nephrectomy on two 2 million and three 5 million SC-islet transplanted mice following diabetes reversal and observed a
return to hyperglycemia 3 days following the nephrectomy
in all mice (Fig. 3F).
Excised grafts from at least one mouse per dose after 14
weeks in vivo, and up to 3 mice at 22 weeks in vivo, further
emphasized the similarity between 5 and 2 million SC-islet
transplanted mice (Fig. 3G, Supplementary Fig. S3B and C). In
both conditions, C-Peptide, GCG, and somatostatin positive
cells indicated the presence of 3 major endocrine cell types
in vitro post engraftment (Fig. 3G, Supplementary Fig. S3B
and C). The 0.75 million cell transplanted graft had a smaller
width for cell detection, as seen in the grafted kidney (Fig.
1B and Supplementary Fig. S1A), containing fewer C-Peptide
expressing SC-β cells compared to a dose of 5 million cells
(Supplementary Fig. S3B). In contrast, a similar proportion
of somatostatin expressing SC-δ and GCG expressing SC-α
cells remained (Supplementary Fig. S3B). Together, these results indicated 2 million SC-islet cells generated with our differentiation protocol provided a similar therapeutic effect as
5 million transplanted cells.

The Diabetic Environment at SC-Islet
Transplantation Did Not Affect Maturation
To continue evaluating different mouse models, we determined the effect of a diabetic environment on SC-islet function
and maturation in vivo. We transplanted 5 million SC-islet
cells into the KC of STZ-induced diabetic and nondiabetic
mice. Mice transplanted with cells gained weight at a similar
rate to healthy, nondiabetic control mice (Supplementary Fig.
S3D). Weekly blood glucose measurements displayed a return to euglycemia for the STZ-treated transplants at 6 weeks
and similar blood glucose levels between the STZ-treated
and nondiabetic transplanted mice at 16 weeks (Fig. 4A).
C-Peptide measurements were similar between STZ-treated
and nondiabetic mice (Fig. 4B and C). To evaluate potential stress on SC-islets transplanted into a diabetic environment, we quantified the human proinsulin/insulin ratio in
mouse serum at 2 weeks post-transplantation. We detected a
similar ratio for SC-islets in both mouse conditions (Fig. 4D),
implying a hyperglycemic mouse environment did not affect
insulin processing. Furthermore, the mice displayed similar
glucose tolerance 6 weeks following SC-islet transplantation
(Fig. 4E).
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Figure 3. Various stem cell-derived islet (SC-islet) doses transplanted into the kidney capsule of diabetic mice. (A) Blood glucose measurements before
and after streptozotocin (STZ) treatment and kidney capsule (KC) transplantation of either 5 (STZ, KC 5M; dark blue; n = 4), 2 (STZ, KC 2M; medium
blue; n = 3), or 0.75 (STZ, KC 0.75M; light blue; n = 4) million SC-islet cells, and diabetic (STZ, No Txp; dark gray; n = 4) controls. (B) Diabetes reversal
curve for each transplant condition (STZ, KC 2M, n = 3; STZ, KC 5M and STZ, KC 0.75M n = 4). (C) Human C-Peptide quantification for random serum
collection from transplanted mice at 2 weeks post-transplantation (STZ, KC 2M, n = 3; STZ, KC 5M and STZ, KC 0.75M n = 4). ∗∗∗∗ P < .0001 by 2-way
unpaired t-test. (D) In vivo GSIS of transplanted mice (STZ, KC 2M, n = 3; STZ, KC 5M and STZ, KC 0.75M n = 4). ∗P < .05, ∗∗P < .01 by 2-way paired
t-test comparing 0- and 60-minutes time points. #P < .05, by 2-way unpaired t-test comparing 60 minutes between doses. (E) Glucose tolerance test
(GTT) blood glucose measurements and area under the curve (AUC) quantification for transplanted and diabetic mice (STZ, KC 2M, n = 3; all other
conditions, n = 4). ∗∗∗P < .001, n.s., not significant, by 2-way unpaired t-test comparing transplant conditions. (F) Blood glucose measurements after
nephrectomy of 2 STZ, KC 2M and 3 STZ, KC 5M mice. (G) Sectioned grafts were explanted and immunostained for all doses at 14 weeks posttransplantation with DAPI (blue) and islet markers. Images are representative of a single graft per dose. Scale bar = 100 µm. See also Supplementary
Fig. S2. Results are mean ± SEM.
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Grafted kidneys from both transplant conditions explanted at week 14- and 22-weeks post-transplantation
contained a similar composition of endocrine cell types represented by C-Peptide, GCG, and somatostatin positive cells
(Supplementary Fig. S3E and F). In both diabetic environments, the transplanted SC-islets had only monohormonal
cells in the graft (Supplementary Fig. S2F). Both STZ and
no STZ grafts had FAM159B and MAFA coexpression with
C-Peptide+ SC-β cells, suggesting the diabetic environment is
independent of in vivo maturation (Fig. 4F). The percentage of
MAFA+ (STZ, 59 ± 4%, No STZ, 37 ± 15%) and FAM159B+
SC-β (C-Peptide+) cells was similar between SC-islet transplants into diabetic and nondiabetic mice (Fig. 4F and G,
Supplementary Fig. S3E). In conclusion, transplanting highfunctioning SC-islets into either STZ-induced diabetic or
nondiabetic mice yielded similar results for maturation of the
SC-β cells, human insulin processing, and random C-Peptide
secretion in the mouse serum.

Discussion
Diabetes cell therapy using differentiated SCs will likely be one
of the first, most widespread uses of cell replacement therapy
technology. To translate diabetes cell therapy to the clinic,
animal models are needed to test the efficacy of SC-islets. This
controlled study evaluated several transplantation parameters
in mice. Our generated results provide a greater understanding
of maturation and function of SC-islets impacted by transplantation strategy, dose, and host diabetic state.
Research groups investigating the potential for SC-islets
and related insulin-producing cell types for diabetes cell
therapy have varied transplantation parameters. In this study,
our transplantation strategies include SQ, IM, and KC sites.
Technical expertise can influence strategy preference with IM
surgeries having a high failure14 and operative mortality rate,34
while SQ transplants are a routine, easy to learn procedure.
Of note, the KC is not a translatable location in human patients. However, it is an ideal location to observe maturation
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Figure 4. Diabetic environment effect on function and maturation of kidney capsule [KC] transplanted stem cell-derived islets (SC-islets). (A) Blood
glucose measurements for streptozotocin (STZ)-treated diabetic (STZ, KC 5M, blue, n = 4) and nondiabetic (No STZ, KC 5M, blue and white stripe,
n = 4) mice transplanted with 5 million SC-islet cells and diabetic (STZ, No Txp, n =4) control mice. (B) Random serum human C-Peptide collected
from transplanted mice at 2 weeks post-transplantation (n = 4). n.s., not significant by 2-way unpaired t-test. (C) In vivo GSIS of transplanted mice.
Human C-Peptide is quantified before and 60 minutes after glucose injection at 6 weeks post-transplantation (n = 4). ∗P < .05 by 2-way paired t-test
comparing 0 and 60 minutes. (D) Ratio of human proinsulin and insulin in mouse serum 2 weeks post-transplantation (n = 4). n.s., not significant
by 2-way unpaired t-test. (E) Glucose tolerance test (GTT) and area under the curve (AUC) quantification for all mouse conditions (n = 4) 6 weeks
following transplantation. n.s., not significant by 2-way unpaired t-test between transplant conditions. (F) Immunostaining of explanted KC grafts for
DAPI (blue) and β cell maturation markers. Images are representative of SC-islets within a single graft for each condition. Scale bar = 100 µm. (G)
Quantification of MAFA+C-Peptide+ cells from total C-Peptide+ cells for multiple SC-islets within a single graft presented as transplanted diabetic
(STZ, KC 5M, n = 8) and nondiabetic (No STZ, KC 5M, n = 4) mice. n.s., not significant by 2-way unpaired t-test. See also Supplementary Fig. S2.
Results are mean ± SEM.
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or an alternative delivery approach than used here to rescue
diabetes. Encapsulation devices are being tested to protect
transplanted cells from the immune system and increase vascularization upon transplantation.22,27,44 A recent report has
shown that a collagen hydrogel formulation can improve islet
efficacy upon transplantation subcutaneously.45 Ongoing clinical trials use immunoprotective encapsulation devices transplanted in the SQ space (NCT04678557, NCT03513939).41,46
Advancements in biocompatible materials for encapsulation
devices are also progressing to create sturdy (polytetrafluoroethylene),47-49 durable (polycaprolactone),50,51 and retrievable
(thread-reinforced alginate fibers)52 devices for islet encapsulation targeting transplantation in the SQ space. Recent
advances in device fabrication demonstrated a biocompatible, safe, and retrievable device using nanospinning with
TSPU and an alginate core to transplant human SC-islets
intraperitoneally in immunocompetent mice and dogs with
minimal immune response.35 Macro- and microencapsulation
strategies8,44,53 and immune cloaking through gene editing54,55
are also being used to evade immunosuppression of transplanted SC-islets and primary human islets. In addition to
protecting the transplanted cells, increasing the proportion of
the SC-β cell population within SC-islets or enhancing function of the SC-β cells would render a lower therapeutic dose
needed for transplantation in patients with diabetes. Several
groups are working on strategies to generate a higher proportion of SC-β cells by sorting pancreatic progenitor and β
cells.7,9,33,56 Combining advances in differentiation protocols,
encapsulation methods, sorting for purified cell populations,
and gene editing to evade the immune system will help generate a diabetes cell replacement therapy.

Conclusion
Here, we demonstrate that common transplantation parameters affect the function and maturation of SC-islets in mice.
As few as 2 million SC-islet cells reversed diabetes but 0.75
million cells were unable to achieve reversal. Transplantation
in the KC resulted in higher serum C-Peptide and better glycemic control compared to IM and SQ sites. In addition, serum
C-Peptide was similar between STZ-treated and nondiabetic
mice. Expression of the maturation markers FAM159B and
MAFA was only achieved by transplantation underneath the
kidney capsule and was unaffected by the diabetic state of
the animal.
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and function of the SC-islets in mice due to its contained location and rapid vascularization.
In this study, we transplanted 0.75, 2, and 5 million SC-islet
cells and demonstrated that lower cell numbers (2 million)
than routinely used for mouse models5-7,17,19,35 are sufficient.
Specifically, previous studies required transplantation of larger
cell doses ranging from approximately 1 to 20 million, derived from various differentiation protocols.12,17,18,20,23,25-27 The
numbers that we transplanted were chosen to span the spectrum of lower doses, as we had previously established that 5
million SC-islet cells were sufficient in the KC of mice5,10 and
we wanted to have a value lower than typical. Reduced differentiation efficiency would require larger doses. Our effective
dose of 2 million cells in mice may be attributed to higher
SC-β cell fractional yields in the SC-islets and/or high function in vitro. Our results demonstrated 0.75 million SC-islet
cells were unable to reach euglycemia following transplant.
Further study into intermediate cell doses would be useful to
better understand this parameter on achieving euglycemia.
In this study, we characterized the maturation of SC-β cells
through elevated C-peptide, a proxy marker for insulin, and
an increased fraction of C-Peptide+/MAFA+ and C-Peptide+/
FAM159B+ β cells. There is heterogeneity of FAM159B in
β cells, which remains unclear.30,36 The impact of transplantation parameters on other islet endocrine cell function and
maturation, such as SC-α, SC-δ, and SC-enterochromaffin
cells, remains unclear. Furthermore, the cross-reactivity of
antibodies, such as the MAFA antibody to MAFB, remains
a possibility. Additional limitations of our study include the
various unevaluated parameters. There are multiple chemicals that can induce diabetes including STZ and alloxan,12
and each needs to be optimized due to variable sensitivity between rodent strains.37 We used exclusively male mice in our
experimental design given the well-documented difficulties
with rendering female mice diabetic by STZ or alloxan.37,38
Alternate primary or SC-islet transplantation strategy sites
not evaluated in our study include the spleen, intraperitoneal
space, omentum, and portal vein. Moreover, the study of the
various transplantation parameters in a larger sample size
would be favorable. Furthermore, there are multiple strains
of rodents used in previous studies to evaluate diabetes cell
therapy, including TCRα−/−, B6-RAG−/−, nonobese diabeticSCID, and SCID-beige mice transplanted with SC-PP2 cells,39
and C57BL/6J mice and nude rats transplanted with SC-PP2
and SC-β cells.20 Rodents are not the most physiologically
relevant animal model to evaluate some transplantation strategies which require larger animal models. Non-primates and
large nonhuman primate models, specifically, are of great importance for preliminary clinical trial data. Additionally, we
transplanted stage 6 terminally differentiated SC-islets while
other groups have used pancreatic progenitors, which were
previously compared.21 Of note, progenitor-derived protocols
and diseased SC-β cells10 can lead to overgrowths or tumor formation, which are not observed in our transplants. Currently,
clinical trials aim to achieve insulin independence in patients
with diabetes by transplanting SC-islets (NCT04786262)40 or
pancreatic progenitors (NCT04678557).41
Several other groups are also working to move the field
forward for clinical translation of diabetes cell therapy. While
transplantation into the mouse KC has been optimized by
many groups for many years,42,43 it is not translatable to humans. Therefore, groups continue efforts to improve the IM
and SQ locations, which may require larger SC-islet doses
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